Automate Your Wheel Strategy on ALEC
With Tiblio's Option Bot, you can configure your own wheel strategy including ALEC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm
Published: November 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alector, Inc. (“Alector” or “the Company”) (NASDAQ: ALEC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm
Published: November 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alector, Inc. (“Alector” or “the Company”) (NASDAQ: ALEC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
Alector Stock Plummets 63% in a Month: Here's What You Need to Know
Published: November 18, 2025 by: Zacks Investment Research
Sentiment: Negative
ALEC stock plunges after its dementia candidate fails to slow disease progression in a late-stage study, prompting job cuts and a strategic pipeline shift.
Read More
After Golden Cross, Alector (ALEC)'s Technical Outlook is Bright
Published: August 22, 2025 by: Zacks Investment Research
Sentiment: Positive
After reaching an important support level, Alector, Inc. (ALEC) could be a good stock pick from a technical perspective. ALEC recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Read More
Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2024, at 8:40 am ET.
Read More
Alector to Participate in Upcoming Healthcare Conferences
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences: Bank of America Securities Health Care Conference (Las Vegas, Nevada) Tuesday, May 13, 2025, at 2:20 p.m.
Read More
Alector, Inc. (ALEC) Q4 2024 Earnings Call Transcript
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Alector, Inc. (NASDAQ:ALEC ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Katie Hogan - Senior Director-Corporate Communications and Investor Relations Arnon Rosenthal - Co-Founder and Chief Executive Officer Gary Romano - Chief Medical Officer Sara Kenkare-Mitra - President and Head, Research and Development Marc Grasso - Chief Financial Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald Alec Stranahan - Bank of America Securities Thomas Shrader - BTIG Yaron Werber - TD Cowen Sarah Schram - William Blair Sam Lee - Mizuho Securities Operator Good afternoon, ladies and gentlemen, and welcome to Alector Fourth …
Read More
Alector (ALEC) Reports Q4 Loss, Tops Revenue Estimates
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Negative
Alector (ALEC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.49 per share a year ago.
Read More
Alector to Participate in Upcoming Healthcare Conferences
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences:
Read More
About Alector, Inc. (ALEC)
- IPO Date 2019-02-07
- Website https://www.alector.com
- Industry Biotechnology
- CEO Arnon Rosenthal
- Employees 175